Neovasc Inc. (NVCN)
| Market Cap | 16.65M |
| Revenue (ttm) | 2.71M |
| Net Income (ttm) | -32.88M |
| Shares Out | 2.73M |
| EPS (ttm) | -9.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,989 |
| Open | 6.21 |
| Previous Close | 6.10 |
| Day's Range | 6.04 - 6.26 |
| 52-Week Range | 4.64 - 28.25 |
| Beta | 2.72 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | May 12, 2022 |
About NVCN
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Financial Performance
In 2021, Neovasc's revenue was $2.55 million, an increase of 30.14% compared to the previous year's $1.96 million. Losses were -$24.89 million, -13.26% less than in 2020.
Financial StatementsNews
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
VANCOUVER and MINNEAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification fro...
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
Neovasc (NVCN) delivered earnings and revenue surprises of -140.80% and 23.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 12, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the qu...
Neovasc to Report First Quarter Financial Results on May 12, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 29, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended March 31, 2022 on...
Neovasc Comments on European Heart Journal Publication
Report demonstrates objective improvements in patients suffering from microvascular dysfunction
Neovasc Announces Effective Date of Share Consolidation
VANCOUVER, BC, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for ...
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX : NVCN) (Neovasc or the Company) today announced that its management team wi...
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
New York, New York--(Newsfile Corp. - April 13, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) "Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its A...
Neovasc Announces Consolidation and Extension of Convertible Debt
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the t...
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
VANCOUVER and MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and...
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 1...
Neovasc Announces German Reimbursement Renewal and Commercial Progress
VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remunera...
Independent Publication Reports Neovasc Reducer™ Demonstrates Cost Savings
VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced the publication of cost-effectiveness ...
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-ef...
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
VANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated...
Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of an arti...
Neovasc Announces Publication Supporting the Neovasc Reducer™ Device
VANCOUVER and MINNEAPOLIS, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “The E...
Neovasc Announces Case Series of First U.S. Reducer Implants Published In Peer-Reviewed Journal
VANCOUVER and MINNEAPOLIS, Jan. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the jou...
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
VANCOUVER and MINNEAPOLIS, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participat...
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
COSIRA-II Trial Designed to Study the Neovasc Reducer(TM) for Patients with Refractory AnginaVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 5, 2022) - Neovasc Inc. (NA...
Neovasc to Participate in Sidoti December Virtual Microcap Conference
VANCOUVER and MINNEAPOLIS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that its management team will be participat...
Neovasc Reducer(TM) System Receives National Reimbursement in France
First therapy to receive newly established French reimbursement designationVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 30, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX...
Neovasc Reducer™ System Receives National Reimbursement in France
First therapy to receive newly established French reimbursement designation
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) has received written notification (the "Nasdaq Notic...
The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Re...
VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced that the United Kingdom's Interventi...